Glifempa M is a chronic condition drug for nutrition and metabolism in the form of anti-diabetic medicine.
Glifempa pills (Empagliflozin) include empagliflozin, a sodium-glucose co-transporter 2 inhibitor that may be used orally (SGLT2).
Sodium-glucose co-transporter 2 (SGLT2) is the main transporter that allows glucose to be reabsorbed from the glomerular filtrate and returned to the circulation.
Empagliflozin is an SGLT2 inhibitor.
Empagliflozin inhibits SGLT2, which decreases renal reabsorption of filtered glucose and lowers the renal glucose threshold, increasing urine glucose excretion.
Empiget Glifempa (Empagliflozin) is used to enhance glycemic control in persons with type 2 diabetes mellitus as an addition to diet and exercise.
- Monotherapy: When diet and exercise alone are insufficient to provide optimal glycemic control in persons for whom metformin is contraindicated owing to intolerance.
- Add-on combination therapy: When other glucose–lowering medical drugs, such as insulin, together with diet and exercise, do not give appropriate glycemic control, add-on combination treatment is used.
HOW TO USE
DOSAGE & ADMINISTRATION:
Monotherapy and add-on combination treatment: The suggested beginning dose for monotherapy and add-on combination therapy with other glucose-lowering medical agents, including insulin, is 10 mg empagliflozin once day with or without meals.
The dose can be raised to 25mg once day in individuals who tolerate 10mg once daily and have an eGFR of 60 ml/min/1.73 m2 and need tighter glycemic control.
The daily maximum dosage is 25mg.
When empagliflozin is used with a sulphonylurea or insulin, a reduced sulphonylurea or insulin dose may be explored to lessen the risk of hypoglycemia.
CONTRAINDICATIONS: Glifempa Empagliflozin is contraindicated in:
- Patients who have a known hypersensitivity to empagliflozin or any of the product’s excipients.
- Dialysis, severe renal impairment, or end-stage renal disease